

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM.

New England journal of medicine

2021; 385(27):2531-2543

ARTICLE IDENTIFIERS

DOI: 10.1056/NEJMoa2108793

PMID: unavailable

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 0028-4793

eISSN: 1533-4406

OCLC ID: 01587974

CONS ID: not available

US National Library of Medicine ID: 0255562

This article was identified from a query of the SafetyLit database.